Cerevel Therapeutics weakness attributed to CTFN report

Shares of Cerevel Therapeutics (CERE) dipped and are down about 2% in Wednesday morning trading. The weakness is being attributed to a report by CTFN, citing a source close to the matter, that a recommendation memo from the staff at the FTC to challenge the company’s planned merger with AbbVie (ABBV) is being considered, contacts tell The Fly.